---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071992"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:27:26.971245+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025

## Summary
- Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.
- Cash and investments $106.9M as of March 31, 2025; expected runway into second half of 2026.
- R&D expenses rose to $17.0M from $13.0M, driven by increased clinical and manufacturing costs for MICVO.
- On track to report Phase 1 monotherapy data for MICVO in HNSCC in H2 2025 and combination with pembrolizumab in H2 2025.
- Preclinical data confirm three-pronged mechanism of MICVO (direct killing, bystander effect, immunogenic cell death).

## SEC filing metadata
- accession: 0000950170-25-071992
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/0000950170-25-071992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/pyxs-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071992
- JSON: https://secwatch.observer/filing/0000950170-25-071992.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.